Mutación del gen BRAF en pacientes con cánceres de colon y recto con KRAS no mutado

Date

2014

Type:

Artículo

item.page.extent

6

item.page.accessRights

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

Sociedad Médica de Santiago

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

item.page.other

item.page.references

Abstract

Background: In colorectal cancer, BRAF and KRAS mutation are mutually exclusive, but both are independent prognostic factors for the disease. Aim: To determine the frequency of BRAF V600E mutation in colorectal cancer. Material and Methods: A KRAS mutation study was carried out in 100 tissue samples of primary and metastatic adenocarcinomas of colon and rectum from patients aged 61.1 ± 62 years (56 women). Negative KRAS mutation cases underwent study of BRAF V600E mutation by restriction fragment length polymorphism (RFLP) and direct sequencing. Results: Primary tumors were located in the colon and rectum in 88 and six cases respectively. Five were liver metastases and in one case, the sample location was undetermined. Forty two samples were KRAS positive (mutated). In 12 of the 58 KRAS negative (wild type) samples, the V600E mutation in codon 15 of the BRAF gene was demonstrated. No differences in the frequency and distribution of mutations, stratified by gender, age, primary tumor versus metastasis, or tumor location were observed. Conclusions: Twelve percent of KRAS negative colorectal cancer samples showed BRAF gene mutation. Considering that 42% of samples have a KRAS mutation, 54% of patients should not respond to therapies with monoclonal antibodies directed against epidermic growth factor (EGFR) pathway.

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Revista Médica de Chile 2014, vol.142,p.55-60

Keywords

Proto-Oncogene Proteins p21 (ras), Proto-Oncogene Proteins B-raf, Mutation, Colonic neoplasms

item.page.dc.rights

item.page.dc.rights.url